Form 4: Elanco EVP Sells Shares for Tax Liability
Insider Transaction Report
Elanco Animal Health's Executive Vice President, Ellen de Brabander, disposed of 8,262 common shares in a pre-planned transaction for tax liability.
Summary
- Ellen de Brabander, Executive Vice President of Research, Development and Regulatory Affairs at Elanco Animal Health Inc. (ELAN), reported a disposition of common stock.
- On March 3, 2026, Ms. de Brabander disposed of 8,262 shares of Elanco common stock.
- The transaction was executed at a price of $24.88 per share.
- The transaction code 'F' indicates that these shares were disposed of to cover tax liabilities incident to the receipt, exercise, or vesting of a security.
- Following this transaction, Ms. de Brabander beneficially owns 260,124 shares of Elanco common stock.
- The transaction was made pursuant to a Rule 10b5-1(c) pre-planned contract, instruction, or written plan.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine, non-discretionary transaction for tax purposes, which typically has a neutral impact on company sentiment as it does not reflect a change in management's confidence or company fundamentals.
Positives
- The transaction was conducted under a Rule 10b5-1(c) plan, indicating a pre-planned and non-discretionary sale, which aligns with good corporate governance practices for insider transactions.
Negatives
- No specific negative implications are evident from this routine, tax-related insider transaction.
Future Outlook
No forward-looking statements or guidance were provided in this filing.
Industry Context
StockSavvy.ai notes this is a routine insider transaction, common for executive compensation vesting and tax obligations, and does not reflect a change in company fundamentals or management's outlook for Elanco Animal Health within the animal health industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Adherence to Insider Trading Policy | The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). | 03/03/2026 | This indicates adherence to robust insider trading policies, enhancing transparency and reducing concerns about opportunistic trading by insiders. |
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in company fundamentals or management's outlook.
Key Dates
| Date | Description |
|---|---|
| 03/03/2026 | Date of transaction where 8,262 shares were disposed of. |
| 03/05/2026 | Date the Statement of Changes in Beneficial Ownership (Form 4) was signed. |
Recommendation
holdThis Form 4 reports a routine, non-discretionary sale of shares by an executive to cover tax liabilities associated with equity compensation. It does not signal a change in the company's fundamentals or management's confidence, thus a 'hold' recommendation is appropriate based solely on this filing.
Keywords
Elanco Animal Health, ELAN, Insider Transaction, Form 4, Stock Sale, Executive Compensation, Tax Liability, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.